veinamitol 1 g or. opl. (pdr.) sachet
negma benelux sa-nv - troxerutine 1 g - poeder voor drank - troxerutine 1 g - troxerutin, combinations
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastische middelen - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
calquence
astrazeneca ab - acalabrutinib - leukemie, lymfocytisch, chronisch, b-cel - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
jaypirca
eli lilly nederland b.v. - pirtobrutinib - lymfoom, mantel-cel - proteïne kinase remmers - treatment of mantle cell lymphoma (mcl).
venoruton 300 mg harde caps.
eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 300 mg - capsule, hard - 300 mg - hydroxyethyl-o-(bèta-)-rutoside 324 mg - troxerutin, combinations
venoruton 1 000 mg sachet
eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 1000 mg - poeder voor oraal gebruik - 1000 mg - hydroxyethyl-o-(bèta-)-rutoside 1000 mg - troxerutin, combinations
venoruton forte 500 mg tabl.
eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 500 mg - tablet - 500 mg - hydroxyethyl-o-(bèta-)-rutoside 500 mg - troxerutin, combinations
ritonavir accord 100 mg filmomhulde tabletten
accord healthcare b.v. winthontlaan 200 3526 kv utrecht - ritonavir 100 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; copovidon (e 1208) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 3350 ; macrogol 400 ; natriumstearylfumaraat ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; sorbitanmonolauraat (e 493) ; talk (e 553 b) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; copovidon ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 3350 ; macrogol 400 ; natriumstearylfumaraat ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; sorbitanmonolauraat (e 493) ; talk (e 553 b) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; copovidon ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 3350 ; macrogol 400 ; natriumstearylfumaraat ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; sorbitanmonolauraat (e 493) ; talk (e 553 b) ; titaandioxide (e 171), - ritonavir
venoruton tabletten 500
healthypharm b.v. van de reijtstraat 31-e 4814 ne breda - hydroxyethylrutosiden 500 mg/stuk - tablet - macrogol 6000 ; magnesiumstearaat (e 470b), - rutoside, combinations